Florez Narjust, Patel Sandip P, Wakelee Heather, Bazhenova Lyudmila, Massarelli Erminia, Salgia Ravi, Stiles Brendon, Peters Solange, Malhotra Jyoti, Gadgeel Shirish M, Nieva Jorge J, Afkhami Michelle, Hirsch Fred R, Gubens Matthew, Cascone Tina, Levy Benjamin, Sabari Joshua, Husain Hatim, Ma Patrick C, Backhus Leah M, Iyengar Puneeth, Lee Percy, Miller Russell, Sands Jacob, Kim Edward
Dana-Farber Cancer Institute, Harvard University School of Medicine, Boston, MA, United States.
Sanford Stem Cell Clinical Center and San Diego Center for Precision Immunotherapy, University of California San Diego, La Jolla, CA, United States.
Oncologist. 2025 Feb 6;30(2). doi: 10.1093/oncolo/oyae228.
Lung cancer is the leading cause of cancer death in the US and globally. The mortality from lung cancer has been declining, due to a reduction in incidence and advances in treatment. Although recent success in developing targeted and immunotherapies for lung cancer has benefitted patients, it has also expanded the complexity of potential treatment options for health care providers. To aid in reducing such complexity, experts in oncology convened a conference (Bridging the Gaps in Lung Cancer) to identify current knowledge gaps and controversies in the diagnosis, treatment, and outcomes of various lung cancer scenarios, as described here. Such scenarios relate to biomarkers and testing in lung cancer, small cell lung cancer, EGFR mutations and targeted therapy in non-small cell lung cancer (NSCLC), early-stage NSCLC, KRAS/BRAF/MET and other genomic alterations in NSCLC, and immunotherapy in advanced NSCLC.
肺癌是美国和全球癌症死亡的主要原因。由于发病率的降低和治疗的进步，肺癌死亡率一直在下降。尽管最近在肺癌靶向治疗和免疫治疗方面取得的成功使患者受益，但这也增加了医疗服务提供者潜在治疗选择的复杂性。为了帮助降低这种复杂性，肿瘤学专家召开了一次会议（弥合肺癌差距会议），以确定各种肺癌情况在诊断、治疗和预后方面当前的知识差距和争议，如下所述。这些情况涉及肺癌中的生物标志物和检测、小细胞肺癌、非小细胞肺癌（NSCLC）中的EGFR突变和靶向治疗、早期NSCLC、NSCLC中的KRAS/BRAF/MET和其他基因组改变，以及晚期NSCLC中的免疫治疗。
